

Diagnostic methods for the control of strongyloidiasis

Virtual meeting, 29 September 2020

Diagnostic methods for the control of strongyloidiasis

Virtual meeting, 29 September 2020



Diagnostic methods for the control of strongyloidiasis, Virtual meeting, 29 September 2020

ISBN 978-92-4-001653-8 (electronic version) ISBN 978-92-4-001654-5 (print version)

© World Health Organization 2020

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Suggested citation. Diagnostic methods for the control of strongyloidiasis, Virtual meeting, 29 September 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. https://creativecommons.org/licenses/by-nc-sa/3.0/igo

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the report of the meeting on thge diagnostic methods for the control of strongyloidiasis and does not necessarily represent the decisions or policies of WHO.

Contents

1			1
2			2
3	Presentations		3
	3.1	Molecular diagnostics	3
	3.2	Serological diagnostics	4
	3.3	Coprological methods	5
	3.4	Panel discussion	5
	3.5	General discussion	7
4	Summary of considerations and decisions		
5	5 Next steps		10
References			11
Aı	nnex	es	
	Age	15	
	List	16	
	Presentations		20

1 Background

A meeting on diagnostic methods for the control of strongyloidiasis was organized by the World Health Organization (WHO) Department of Control of Neglected Tropical Diseases (Geneva, Switzerland) in collaboration with the WHO Collaborating Center on strongyloidiasis and other neglected tropical diseases (Negrar, Italy) and the Federation University (Melbourne, Australia). Children Without Worms (Decatur (GA), USA) provided logistic support. The agenda is attached as *Annex 1* and the list of participants as *Annex 2*.

Dr Zeno Bisoffi and Dr Antonio Montresor welcomed the participants and reported that there were no conflicts of interest to be declared by participants.

In his opening presentation, Dr Montresor shared the good progress in preventive chemotherapy coverage for *Ascaris lumbricoides, Trichuris trichiura* and hookworms. The main reason why no specific activities for *Strongyloides stercoralis* had been implemented so far was because of the poor availability of ivermectin outside the context of elimination programmes for lymphatic filariasis and onchocerciasis. He expects this to change soon, as two generic formulations of ivermectin are in the prequalification process with WHO. Moreover, strongyloidiasis is now included in the WHO road map for neglected tropical diseases for 2021–2030 as an additional soil-transmitted helminth parasite targeted for control.

WHO hopes to enable rapid expansion of strongyloidiasis control programmes using the existing infrastructure for other neglected tropical disease (NTD) control or elimination programmes, as was done to add schistosomiasis.

The preliminary steps for implementing a strongyloidiasis control programme were shared, namely:

- gain knowledge of the epidemiology of S. stercoralis;
- conduct a field evaluation of the proposed intervention. Pilot interventions should evaluate the impact and feasibility of the proposed strategy (a pilot study is planned in Ethiopia); and
- find a standard diagnostic tool to enable assessment of the public health burden of the disease and exchange of information among different research and control groups; for many countries there is no epidemiological information at all, so we need recommendations for assessment of baseline prevalence.

2 Objective of the meeting

The meeting addressed the last key area, that is, determining the best method or combination of diagnostic methods for a control programme for *S. stercoralis* infections in humans.

Dr Montresor's presentation highlighted that while there is currently no "gold standard" for the diagnosis of *S. stercoralis*, there is a felt urgency to optimize diagnostic regimens that are currently available, and in the context of population-based testing (as opposed to individual focused diagnostics in clinical settings). In other words, the diagnostic test(s) should have good accuracy, but we should remember that in public health we do not aim at individual diagnosis: rather, we need a tool that should help to estimate the prevalence in a population (see *Annex 3: presentation 1*).

